Clinical Trial Update: Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial compared pramipexole extended-release to immediate-release in Chinese Parkinson's disease patients and posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Mirapex (pramipexole)
• Mirapex ER (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-01-24